A Phase I Study of Modified Vaccinia Ankara With Mosaic HIV Inserts in Healthy, HIV-Uninfected Adults, Some of Whom Have Previously Received an Adenovirus Type 26 ENVA.01 Vaccine

Trial Profile

A Phase I Study of Modified Vaccinia Ankara With Mosaic HIV Inserts in Healthy, HIV-Uninfected Adults, Some of Whom Have Previously Received an Adenovirus Type 26 ENVA.01 Vaccine

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs MVA mosaic HIV vaccine-Crucell Holland (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms MENSCH
  • Sponsors Crucell Holland
  • Most Recent Events

    • 03 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Apr 2015 Planned number of patients changed from 40 to 25 as reported by ClinicalTrials.gov record.
    • 19 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top